Cargando…
Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
Cholangiocarcinoma (CCA) is a highly lethal gastrointestinal malignancy that has one of the worst prognoses among solid tumors. The combination of Gemcitabine + Cisplatin (GEM/CIS) remains the standard first-line treatment for advanced stage CCA. However, this drug combination yields only a modest o...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748615/ https://www.ncbi.nlm.nih.gov/pubmed/36531039 http://dx.doi.org/10.3389/fonc.2022.1021632 |
_version_ | 1784849860128669696 |
---|---|
author | Prasopporn, Sunisa Suppramote, Orawan Ponvilawan, Ben Jamyuang, Chanette Chanthercrob, Jantappapa Chaiboonchoe, Amphun More-Krong, Pimkanya Kongsri, Kamonchanok Suntiparpluacha, Monthira Chanwat, Rawisak Korphaisarn, Krittiya Okada, Seiji Sampattavanich, Somponnat Jirawatnotai, Siwanon |
author_facet | Prasopporn, Sunisa Suppramote, Orawan Ponvilawan, Ben Jamyuang, Chanette Chanthercrob, Jantappapa Chaiboonchoe, Amphun More-Krong, Pimkanya Kongsri, Kamonchanok Suntiparpluacha, Monthira Chanwat, Rawisak Korphaisarn, Krittiya Okada, Seiji Sampattavanich, Somponnat Jirawatnotai, Siwanon |
author_sort | Prasopporn, Sunisa |
collection | PubMed |
description | Cholangiocarcinoma (CCA) is a highly lethal gastrointestinal malignancy that has one of the worst prognoses among solid tumors. The combination of Gemcitabine + Cisplatin (GEM/CIS) remains the standard first-line treatment for advanced stage CCA. However, this drug combination yields only a modest objective response rate, and in cases that initially respond to this treatment, drug resistance commonly rapidly develops. To improve the efficiency of GEM/CIS therapy for CCA, a thorough understanding of the mechanism of GEM/CIS resistance in CCA is required. To that end – in this study, we developed several acquired GEM/CIS-resistant CCA cell lines and we screened those cell lines for acquired vulnerability. The screening process revealed that subset of CCA with GEM/CIS resistance acquired vulnerability to the small-molecule second mitochondrial-derived activator of caspases (SMAC) mimetics LCL161 and Birinapant. The observed acquired vulnerability was found to be associated with upregulation of an inhibitor of apoptosis protein 2 (cIAP2), a known target of SMAC mimetics. LCL161 or cIAP2-shRNA downregulated cIAP2 and restored the sensitivity to GEM/CIS in GEM/CIS-resistant CCA cell lines and in in vivo GEM/CIS-resistant xenograft models. A strong synergic effect was observed when LCL161 was added to GEM/CIS. Interestingly, this synergism was also observed in drug-naïve CCA cell lines, xenografts, and patient-derived organoids. This triplet therapy also prevented the emergence of multidrug-resistant CCA in in vitro and in vivo models. Our findings suggest that activation of cIAP2 allows CCA to escape GEM/CIS, and that suppression of cIAP2 reestablishes the apoptotic profile of CCA, thus restoring its vulnerability to GEM/CIS. The results of this study indicate that combining the SMAC mimetic LCL161 with GEM/CIS inhibits and prevents the emergence of multidrug resistance in CCA. |
format | Online Article Text |
id | pubmed-9748615 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97486152022-12-15 Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma Prasopporn, Sunisa Suppramote, Orawan Ponvilawan, Ben Jamyuang, Chanette Chanthercrob, Jantappapa Chaiboonchoe, Amphun More-Krong, Pimkanya Kongsri, Kamonchanok Suntiparpluacha, Monthira Chanwat, Rawisak Korphaisarn, Krittiya Okada, Seiji Sampattavanich, Somponnat Jirawatnotai, Siwanon Front Oncol Oncology Cholangiocarcinoma (CCA) is a highly lethal gastrointestinal malignancy that has one of the worst prognoses among solid tumors. The combination of Gemcitabine + Cisplatin (GEM/CIS) remains the standard first-line treatment for advanced stage CCA. However, this drug combination yields only a modest objective response rate, and in cases that initially respond to this treatment, drug resistance commonly rapidly develops. To improve the efficiency of GEM/CIS therapy for CCA, a thorough understanding of the mechanism of GEM/CIS resistance in CCA is required. To that end – in this study, we developed several acquired GEM/CIS-resistant CCA cell lines and we screened those cell lines for acquired vulnerability. The screening process revealed that subset of CCA with GEM/CIS resistance acquired vulnerability to the small-molecule second mitochondrial-derived activator of caspases (SMAC) mimetics LCL161 and Birinapant. The observed acquired vulnerability was found to be associated with upregulation of an inhibitor of apoptosis protein 2 (cIAP2), a known target of SMAC mimetics. LCL161 or cIAP2-shRNA downregulated cIAP2 and restored the sensitivity to GEM/CIS in GEM/CIS-resistant CCA cell lines and in in vivo GEM/CIS-resistant xenograft models. A strong synergic effect was observed when LCL161 was added to GEM/CIS. Interestingly, this synergism was also observed in drug-naïve CCA cell lines, xenografts, and patient-derived organoids. This triplet therapy also prevented the emergence of multidrug-resistant CCA in in vitro and in vivo models. Our findings suggest that activation of cIAP2 allows CCA to escape GEM/CIS, and that suppression of cIAP2 reestablishes the apoptotic profile of CCA, thus restoring its vulnerability to GEM/CIS. The results of this study indicate that combining the SMAC mimetic LCL161 with GEM/CIS inhibits and prevents the emergence of multidrug resistance in CCA. Frontiers Media S.A. 2022-11-30 /pmc/articles/PMC9748615/ /pubmed/36531039 http://dx.doi.org/10.3389/fonc.2022.1021632 Text en Copyright © 2022 Prasopporn, Suppramote, Ponvilawan, Jamyuang, Chanthercrob, Chaiboonchoe, More-Krong, Kongsri, Suntiparpluacha, Chanwat, Korphaisarn, Okada, Sampattavanich and Jirawatnotai https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Prasopporn, Sunisa Suppramote, Orawan Ponvilawan, Ben Jamyuang, Chanette Chanthercrob, Jantappapa Chaiboonchoe, Amphun More-Krong, Pimkanya Kongsri, Kamonchanok Suntiparpluacha, Monthira Chanwat, Rawisak Korphaisarn, Krittiya Okada, Seiji Sampattavanich, Somponnat Jirawatnotai, Siwanon Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma |
title | Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma |
title_full | Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma |
title_fullStr | Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma |
title_full_unstemmed | Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma |
title_short | Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma |
title_sort | combining the smac mimetic lcl161 with gemcitabine plus cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9748615/ https://www.ncbi.nlm.nih.gov/pubmed/36531039 http://dx.doi.org/10.3389/fonc.2022.1021632 |
work_keys_str_mv | AT prasoppornsunisa combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT suppramoteorawan combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT ponvilawanben combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT jamyuangchanette combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT chanthercrobjantappapa combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT chaiboonchoeamphun combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT morekrongpimkanya combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT kongsrikamonchanok combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT suntiparpluachamonthira combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT chanwatrawisak combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT korphaisarnkrittiya combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT okadaseiji combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT sampattavanichsomponnat combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma AT jirawatnotaisiwanon combiningthesmacmimeticlcl161withgemcitabinepluscisplatintherapyinhibitsandpreventstheemergenceofmultidrugresistanceincholangiocarcinoma |